CL2015002181A1 - Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. - Google Patents

Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.

Info

Publication number
CL2015002181A1
CL2015002181A1 CL2015002181A CL2015002181A CL2015002181A1 CL 2015002181 A1 CL2015002181 A1 CL 2015002181A1 CL 2015002181 A CL2015002181 A CL 2015002181A CL 2015002181 A CL2015002181 A CL 2015002181A CL 2015002181 A1 CL2015002181 A1 CL 2015002181A1
Authority
CL
Chile
Prior art keywords
laquinimod
multiple sclerosis
treatment
progressive forms
progressive
Prior art date
Application number
CL2015002181A
Other languages
English (en)
Spanish (es)
Inventor
Nora Tarcic
Dan Bar-Zohar
Liat Hayardeny
Sherki Yossi Gilgun
Tali Gorfine
Volker Knappertz
Ella Sorani
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002181(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2015002181A1 publication Critical patent/CL2015002181A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
CL2015002181A 2013-02-15 2015-08-05 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. CL2015002181A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03

Publications (1)

Publication Number Publication Date
CL2015002181A1 true CL2015002181A1 (es) 2016-06-03

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002181A CL2015002181A1 (es) 2013-02-15 2015-08-05 Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.

Country Status (18)

Country Link
US (2) US20140235670A1 (enExample)
EP (1) EP2956137A4 (enExample)
JP (1) JP2016510343A (enExample)
KR (1) KR20150119227A (enExample)
CN (1) CN105163737A (enExample)
AU (1) AU2014216199A1 (enExample)
BR (1) BR112015019564A2 (enExample)
CA (1) CA2900503A1 (enExample)
CL (1) CL2015002181A1 (enExample)
EA (1) EA201591507A1 (enExample)
HK (2) HK1218251A1 (enExample)
IL (1) IL240014A0 (enExample)
MX (1) MX2015010296A (enExample)
PE (1) PE20151526A1 (enExample)
SG (1) SG11201505818WA (enExample)
TW (1) TW201442709A (enExample)
UY (1) UY35328A (enExample)
WO (1) WO2014127139A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
UY36099A (es) * 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
US10537566B2 (en) 2014-10-16 2020-01-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP7193448B2 (ja) 2016-08-31 2022-12-20 マピ ファーマ リミテッド 酢酸グラチラマーを含むデポシステム
CN110382052A (zh) * 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US20230296628A1 (en) * 2020-07-09 2023-09-21 Oklahoma Medical Research Foundation Biomarkers for Identifying Relapses in Multiple Sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
BRPI0713694A2 (pt) * 2006-06-12 2012-10-30 Teva Pharma composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica
BRPI0814624A2 (pt) * 2007-07-11 2015-01-27 Medicinova Inc Tratamento de doença neurodegenerativa progresiva com ibudilaste
TW201438738A (zh) * 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
BRPI0922871A2 (pt) * 2008-12-11 2016-11-16 Biovista Inc metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
CN107308162A (zh) * 2009-06-19 2017-11-03 泰华制药工业有限公司 利用拉喹莫德治疗多发性硬化
UA111959C2 (uk) * 2010-12-07 2016-07-11 Тева Фармасьютікл Індастріз Лтд. Застосування лаквінімоду для зменшення втоми, поліпшення функціонального стану та поліпшення якості життя у пацієнтів з розсіяним склерозом
WO2013016686A1 (en) * 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
EA201590726A1 (ru) * 2012-10-12 2015-10-30 Тева Фармасьютикал Индастриз Лтд. Лахинимод для уменьшения таламического поражения при рассеянном склерозе
UY36099A (es) * 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad

Also Published As

Publication number Publication date
BR112015019564A2 (pt) 2017-07-18
EP2956137A1 (en) 2015-12-23
US20140235670A1 (en) 2014-08-21
PE20151526A1 (es) 2015-11-20
HK1218251A1 (zh) 2017-02-10
US20180064702A1 (en) 2018-03-08
CA2900503A1 (en) 2014-08-21
EP2956137A4 (en) 2016-08-03
TW201442709A (zh) 2014-11-16
UY35328A (es) 2014-09-30
JP2016510343A (ja) 2016-04-07
SG11201505818WA (en) 2015-08-28
IL240014A0 (en) 2015-09-24
AU2014216199A1 (en) 2015-09-03
CN105163737A (zh) 2015-12-16
HK1218254A1 (zh) 2017-02-10
EA201591507A1 (ru) 2015-12-30
KR20150119227A (ko) 2015-10-23
MX2015010296A (es) 2016-05-05
WO2014127139A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
UY34720A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fumarato de dimetilo
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
EP3177311C0 (en) COMBINATION OF MEDICINAL PRODUCTS CONTAINING CABOZANTINIB AND A PROTEASOME INHIBITOR FOR THE TREATMENT OF MULTIPLE MYELOMA
NZ756329A (en) Combination of a ppar agonist with a fxr agonist
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
CL2015002666A1 (es) Formas de dosificación sólidas de antiemético de liberación prolongada
UY35823A (es) Profármacos de antagonista de nmda
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
EA201690446A1 (ru) Лечение множественной миеломы
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac
MX2017012449A (es) Tratamiento del dolor.
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
BR112015019792A2 (pt) composição para tratamento de hemorróidas e método de preparação
AR094809A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
LT2988782T (lt) Dozavimo formos, skirtos peroraliniam veikliųjų medžiagų vartojimui